Department of Thoracic and Vascular Surgery and Heart-Lung Transplantation, Marie-Lannelongue Hospital, Paris-Sud University, Le Plessis Robinson, France.
Research and Innovation Unit, INSERM U999, DHU TORINO, Paris-Sud University, Marie Lannelongue Hospital, Le Plessis Robinson, France.
Eur J Cardiothorac Surg. 2018 Aug 1;54(2):341-347. doi: 10.1093/ejcts/ezy089.
Extracorporeal membrane oxygenation (ECMO) has become the standard of cardiopulmonary support during a sequential double lung transplant for pulmonary hypertension. Whether central or peripheral cannulation is the best strategy for these patients remains unknown. Our goal was to determine which is the best strategy by comparing 2 populations of patients.
We performed a single-centre retrospective study based on an institutional prospective lung transplant database.
Between January 2011 and November 2016, 103 patients underwent double lung transplant for pulmonary hypertension. We compared 54 patients who had central ECMO (cECMO group) to 49 patients who had peripheral ECMO (pECMO group). The pECMO group had significantly more bridged patients who received emergency transplants (31% vs 6%, P = 0.001). The incidence of Grade 3 primary graft dysfunction requiring ECMO (14% vs 11%, P = not significant) and of in-hospital mortality (11% vs 14%, P = not significant) was similar between the groups. Groin infections (16% vs 4%, P = 0.031), deep vein thrombosis (27% vs 11%, P = 0.044) and lower limb ischaemia (12% vs 2%, P = 0.031) occurred significantly more often in the pECMO group. The number of chest reopenings for bleeding or infection was similar between the groups. The 3-month, 1-year and 5-year survival rates did not differ between the groups (P = 0.94).
Central or peripheral ECMO produced similar results during double lung transplant for pulmonary hypertension in terms of in-hospital deaths and long-term survival rates. Central ECMO provided satisfactory results without major bleeding provided the patient was weaned from ECMO at the end of the procedure. Despite the rate of groin and lower limb complications, peripheral cannulation remained the preferred solution to bridge the patient to transplant or for postoperative support.
体外膜肺氧合(ECMO)已成为肺动脉高压序贯双肺移植时心肺支持的标准。对于这些患者,中心或外周插管哪种策略最佳仍不清楚。我们的目标是通过比较 2 组患者来确定哪种策略最佳。
我们基于机构前瞻性肺移植数据库进行了一项单中心回顾性研究。
2011 年 1 月至 2016 年 11 月,103 例肺动脉高压患者接受了双肺移植。我们比较了 54 例接受中心 ECMO(cECMO 组)的患者和 49 例接受外周 ECMO(pECMO 组)的患者。pECMO 组中有更多接受紧急移植的桥接患者(31%比 6%,P=0.001)。两组中,需要 ECMO 的 3 级原发性移植物功能障碍的发生率(14%比 11%,P=无显著差异)和院内死亡率(11%比 14%,P=无显著差异)相似。pECMO 组中,腹股沟感染(16%比 4%,P=0.031)、深静脉血栓形成(27%比 11%,P=0.044)和下肢缺血(12%比 2%,P=0.031)的发生率显著更高。两组中因出血或感染而再次开胸的次数相似。两组的 3 个月、1 年和 5 年生存率无差异(P=0.94)。
在肺动脉高压的双肺移植中,中心或外周 ECMO 在院内死亡率和长期生存率方面的结果相似。只要患者在手术结束时能成功撤离 ECMO,中心 ECMO 就能提供满意的结果,而不会发生严重出血。尽管存在腹股沟和下肢并发症的发生率,外周插管仍然是桥接患者进行移植或术后支持的首选方法。